Ascorbic Acid Injection, all strengths and all presentations including a) 500 mg/mL, b) corn source 500 mg/mL, c) tapioca 500 mg/mL, d) cassave 500; Rx only, Green Valley Drugs, 1850 Whitney Mesa, #180, Henderson, NV 89014.
Publicado el 22 de mayo de 2013 · Inicio del retiro: 10 de abril de 2013
Resumen
FDA registra el retiro D-342-2013 de medicamentos de Clase II, publicado el 22 de mayo de 2013 e iniciado el 10 de abril de 2013. Empresa responsable: FVS Holdings, Inc. dba. Green Valley Drugs; Estado: Finalizado; Cantidad reportada: 2682 vials; Lote: Lot #: a) 20130313-M, Exp 6/13/2013; 20130306-N, Exp 6/6/2013; 20130220-E, Exp 5/20/2013; 20130222-D, Exp 5/22/2013; 20130205-B, Exp 5/5/2013; 20130205-C, Exp 5/5/2013; 20130222-F, Exp 5/22/2013; 20130315-H, Exp 6/15/2013; 20130313-L, Exp 6/16/2013; 20130306-O, Exp 6/6/2013; 20130328-A, Exp 6/28/2013; 20130404-F, Exp 7/4/2013; 20130333-B, Exp 6/30/2013; 20130301-D, Exp 6/1/2013; 20130311-H, Exp 6/11/2013; 20130328-A, Exp 6/28/2013; 20130404-D, Exp 7/4/2013; 20130404-E, Exp 7/4/2013; 20130315-G, Exp 6/15/2013; 20130322-G, Exp 6/22/2013; 20130228-D, Exp 5/28/2013; 20130205-B, Exp 5/5/2013; b) 20130315-G, Exp 6/15/2013; 20130322-G, Exp 6/22/2013; c) 1302121000AE, Exp 5/12/2013; 20130322-C, Exp 6/22/2013; 20130401-C, Exp 7/1/2013; 20130131-D, Exp 4/30/2013; 20130213-A, Exp 5/13/2013; 20130305-G, Exp 6/5/2013; 20130131-B, Exp 4/30/2013; 20130201-D, Exp 5/1/2013; 2013201-G, Exp 5/1/2013; 20130222-E, Exp 5/22/2013; 20130322-B, Exp 6/22/2013; 20130131-C, Exp 4/30/2013; 20130131-E, Exp 4/30/2013; 20130213-A, 5/13/2013; 20130201-A, Exp 5/2/2013; 20130221-T, Exp 5/21/2013; 20130311-D, Exp 6/11/2013; 20130311-C, Exp 6/11/2013; 20130311-B, Exp 6/11/2013; 20130314-A, Exp 6/14/2013; 20130314-B, Exp 6/14/2013; 20130315-D, Exp 6/15/2013; 20130304-A, Exp 6/4/2013; 20130318-L, Exp 6/18/2013; 20130325-B, Exp 6/25/2013; 20130318-M, Exp 6/18/2013; d) 20130128-C, Exp 4/28/2013; 20130124J, Exp 4/24/2013; 20130403-C, Exp 7/3/2013; 20130124-J, Exp 4/24/2013, 20130115-I, Exp 4/15/2013. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Lack of Assurance of Sterility: all sterile products compounded, repackaged, and distributed by this compounding pharmacy due to lack of sterility assurance and concerns associated with the quality control processes.
Qué hacer
Voluntary: Firm initiated · Press Release
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- FVS Holdings, Inc. dba. Green Valley Drugs
- Distribuidor
- Nationwide
- Lote
- Lot #: a) 20130313-M, Exp 6/13/2013; 20130306-N, Exp 6/6/2013; 20130220-E, Exp 5/20/2013; 20130222-D, Exp 5/22/2013; 20130205-B, Exp 5/5/2013; 20130205-C, Exp 5/5/2013; 20130222-F, Exp 5/22/2013; 20130315-H, Exp 6/15/2013; 20130313-L, Exp 6/16/2013; 20130306-O, Exp 6/6/2013; 20130328-A, Exp 6/28/2013; 20130404-F, Exp 7/4/2013; 20130333-B, Exp 6/30/2013; 20130301-D, Exp 6/1/2013; 20130311-H, Exp 6/11/2013; 20130328-A, Exp 6/28/2013; 20130404-D, Exp 7/4/2013; 20130404-E, Exp 7/4/2013; 20130315-G, Exp 6/15/2013; 20130322-G, Exp 6/22/2013; 20130228-D, Exp 5/28/2013; 20130205-B, Exp 5/5/2013; b) 20130315-G, Exp 6/15/2013; 20130322-G, Exp 6/22/2013; c) 1302121000AE, Exp 5/12/2013; 20130322-C, Exp 6/22/2013; 20130401-C, Exp 7/1/2013; 20130131-D, Exp 4/30/2013; 20130213-A, Exp 5/13/2013; 20130305-G, Exp 6/5/2013; 20130131-B, Exp 4/30/2013; 20130201-D, Exp 5/1/2013; 2013201-G, Exp 5/1/2013; 20130222-E, Exp 5/22/2013; 20130322-B, Exp 6/22/2013; 20130131-C, Exp 4/30/2013; 20130131-E, Exp 4/30/2013; 20130213-A, 5/13/2013; 20130201-A, Exp 5/2/2013; 20130221-T, Exp 5/21/2013; 20130311-D, Exp 6/11/2013; 20130311-C, Exp 6/11/2013; 20130311-B, Exp 6/11/2013; 20130314-A, Exp 6/14/2013; 20130314-B, Exp 6/14/2013; 20130315-D, Exp 6/15/2013; 20130304-A, Exp 6/4/2013; 20130318-L, Exp 6/18/2013; 20130325-B, Exp 6/25/2013; 20130318-M, Exp 6/18/2013; d) 20130128-C, Exp 4/28/2013; 20130124J, Exp 4/24/2013; 20130403-C, Exp 7/3/2013; 20130124-J, Exp 4/24/2013, 20130115-I, Exp 4/15/2013.
- Clasificación de riesgo
- Class II
- Área (FDA)
- drug
- País
- United States
Retiros relacionados
- FDAMedroxyprogesterone Acetate Injection, all strengths and all presentations including a) Medroxyprogesterone22 de mayo de 2013
- FDAMIC Vitamin Injection, all strengths and all presentations including a) MIC 25-50-25-30 mL, b)22 de mayo de 2013
- FDAMethylprednisolone and Dexamethasone Injection, all strengths and all presentations including a) Methylpred/22 de mayo de 2013
- FDAMethylprednisolone and Bupivacaine Injection, all strengths and all presentations including22 de mayo de 2013
- FDAAmikacin Injection, all strengths and all presentations including 50, 30 mL, Rx only, Green Valley Drugs, 185022 de mayo de 2013
- FDABetamethasone Acetate and Betamethasone Sodium Injection, all strengths and all presentations including 622 de mayo de 2013
Preguntas sobre este retiro
¿Ascorbic Acid Injection, all strengths and all presentations including a) 500 mg/mL, b) corn source 500 mg/mL, c) tapioca 500 mg/mL, d) cassave 500; Rx only, Green Valley Drugs, 1850 Whitney Mesa, #180, Henderson, NV 89014. fue retirado del mercado?
Sí. FDA publicó el retiro D-342-2013 el 22 de mayo de 2013. Peligro reportado: Lack of Assurance of Sterility: all sterile products compounded, repackaged, and distributed by this compounding pharmacy due to lack of sterility assurance and concerns associated with the quality control processes.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Press Release